First AD

Second AD

Bladder cancer specialists discuss enfortumab vedotin and the role of antibody-drug conjugates in the treatment landscape.

Enfortumab Vedotin and the Role of ADCs in Bladder Cancer

Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

ESMO 2023: Immunotherapy Advancements in Bladder Cancer

Cleveland Clinic

Cancer Centers

Partner

Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

Monitoring Patients With NMIBC

Bladder Cancer: Treatment Options and Managing Adverse Effects

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

Approach to Collaborative Care in Bladder Cancer

Key Takeaways on Evolving Bladder Cancer Treatment Landscape